Literature DB >> 12461565

Lymphoid malignancies: the dark side of B-cell differentiation.

A L Shaffer1, Andreas Rosenwald, Louis M Staudt.   

Abstract

When the regulation of B-cell differentiation and activation is disrupted, lymphomas and leukaemias can occur. The processes that normally create immunoglobulin diversity might be misdirected, resulting in oncogenic chromosomal translocations that block differentiation, prevent apoptosis and/or promote proliferation. Prolonged or unregulated antigenic stimulation might contribute further to the development and progression of some malignancies. Lymphoid malignancies often resemble normal stages of B-cell differentiation, as shown by molecular techniques such as gene-expression profiling. The similarities and differences between malignant and normal B cells indicate strategies for the treatment of these cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12461565     DOI: 10.1038/nri953

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  124 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

2.  Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Authors:  Murali Janakiram; Venu K Thirukonda; Matthew Sullivan; Adam M Petrich
Journal:  Curr Treat Options Oncol       Date:  2012-02-02

Review 3.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

4.  The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.

Authors:  Philip Brown; Teresa Marafioti; Rajko Kusec; Alison H Banham
Journal:  J Mol Histol       Date:  2005-05       Impact factor: 2.611

5.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 6.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

7.  Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients.

Authors:  Pumza Magangane; Raveendra Sookhayi; Dhirendra Govender; Richard Naidoo
Journal:  J Mol Histol       Date:  2016-10-01       Impact factor: 2.611

8.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

Review 9.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 10.  A conformation-induced oligomerization model for B cell receptor microclustering and signaling.

Authors:  Pavel Tolar; Susan K Pierce
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.